PATENT OFFICE REJECTS LIPITOR PATENT ON PUBPAT'S REQUEST: Public Interest Group's Review Results in All 44 Claims of Pfizer's Patent on Multi-Billion Dollar Drug Ruled Invalid
Relying on evidence provided by PUBPAT when the reexamination was requested, the Patent Office rejected all 44 claims in the pharmaceutical giant's patent. Pfizer has the opportunity to respond to the Patent Office's rejection, but third party requests for reexamination, like the one filed by PUBPAT, result in having the subject patent either modified or completely revoked roughly 70% of the time.
Although the rejected patent is one of five patents listed by Pfizer with the U.S. Food and Drug Administration (FDA) for atorvastatin, the generic name for the drug compound distributed under the Lipitor brand, it is the only one asserted by Pfizer in roughly two dozen patent infringement lawsuits filed last year against web sites selling generic atorvastatin to Americans. Two of the other listed patents are under review by a Delaware court and the remaining two have never been asserted by Pfizer against any competitor to Lipitor.
"The Patent Office has agreed with our conclusion that it should have never granted Pfizer the Lipitor patent," said Dan Ravicher, PUBPAT's Executive Director. "Revoking Pfizer's patent is a critical step towards providing American consumers with access to atorvastatin at a fair price, which will not only provide substantial economic benefit, but will also improve public health, as even Pfizer admits that many Americans in need of the drug are not getting it."
More information about the reexamination of Pfizer's Lipitor patent, including a copy of the Patent Office's Office Action rejecting all of its claims, can be found at PUBPAT > Pfizer Lipitor Patent.